Artelo Biosciences, Inc.
ARTL Nasdaq
SEC CIK 1621221
Follow Artelo Biosciences
Weekly email: filings, results, news
Net income
−$2.4M
+24.7% vs same quarter last year
EPS, diluted
−$0.89
+94.7% vs same quarter last year
Operating cash flow
−$5M
−879.2% vs same quarter last year
Operating income
−$2.5M
+20.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$12.9M |
| FY24 | −$9.8M |
| FY23 | −$9.3M |
| FY22 | −$10.1M |
| FY21 | −$7.4M |
| FY20 | −$4.7M |
| FY19 | −$2.2M |
| FY18 | −$2.3M |
| FY17 | −$234.9K |
| FY16 | −$29.7K |
| FY15 | −$15.2K |
| FY14 | −$15.3K |
News
No stories filed under Artelo Biosciences yet - coverage appears here as the news feed clusters it.